Isatuximab risk minimisation materials: managing risk of interference with blood compatibility tests
Isatuximab can bind to CD38 on RBCs and is associated with a risk of interference with blood compatibility tests (e.g. false positive indirect Coombs test). This brochure for healthcare professionals and blood banks contains information on appropriate measures to manage this.
Source:
electronic Medicines compendium
SPS commentary:
A patient alert card is also available and this should be provided to anyone receiving treatment with isatuximab. They should be advised of the importance of carrying this with them at all times during their treatment, and they must show it to any healthcare professionals treating them both during and for 6 months after treatment is discontinued.